Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Cancer Cell International
Published in: Cancer Cell International 1/2014

Open Access 01-12-2014 | Primary research

A polymethoxyflavone from Laggera pterodonta induces apoptosis in imatinib-resistant K562R cells via activation of the intrinsic apoptosis pathway

Authors: Changshu Cao, Bailian Liu, Chengwu Zeng, Yuhong Lu, Shaohua Chen, Lijian Yang, Bo Li, Yaolan Li, Yangqiu Li

Published in: Cancer Cell International | Issue 1/2014

Login to get access

Abstract

Background

Treatment with imatinib mesylate (IM) (a tyrosine kinase inhibitor) is the first line of standard care for patients newly diagnosed with CML. Despite the success of IM and other tyrosine kinase inhibitors (TKIs), chronic myeloid leukemia (CML) remains largely incurable, and a number of CML patients die due to Abl mutation-related drug resistance and blast crisis. 3, 5-Dihydroxy-6, 7, 3′4′-tetramethoxyflavone (DHTMF) is a polymethoxyflavone isolated from Laggera pterodonta which is a herbal medicine used to treat cancer in the Chinese folk. In the previous study, we found DHTMF demonstrated good antiproliferative activities against a number of cancer cell lines and induced the apoptosis of CNE cells in vitro in a time- and dose-dependent manner while exhibiting low cytotoxicity in the two normal cell lines Vero and EVC304. The aim of the present study was to evaluate the proliferation inhibition and apoptosis induced by DHTMF alone and in combination with IM in the IM-resistant CML cell line K562R.

Methods

Cell proliferation was assayed with the cell counting kit-8 (CCK8) method. The apoptosis percentage was determined by flow cytometry (FCM). Mitochondrial transmembrane potential was detected using FCM and confocal laser-scanning microscopy. The level of proteins involved in apoptosis was detected by Western blotting.

Results

DHTMF suppressed K562R cell viability in both time- and dose-dependent manners. DHTMF combined with IM enhanced the inhibitory effects and apoptosis in K562R cells as compared with DHTMF alone. DHTMF alone and in combination with IM significantly decreased the mitochondrial membrane potential and increased the levels of cleaved caspase-9, caspase-7, caspase-3, and PARP in K562R cells.

Conclusions

We demonstrated that DHTMF could inhibit IM-resistant K562R cell proliferation and induces apoptosis via the intrinsic mitochondrial apoptotic pathway. These results suggest that DHTMF may be a potential therapeutic drug with lower side effects against IM resistance in CML cells.
Appendix
Available only for authorised users
Literature
1.
Goldman JM, Melo JV: Chronic myeloid leukemia–advances in biology and new approaches to treatment. N Engl J Med. 2003, 349 (15): 1451-1464. 10.1056/NEJMra020777.CrossRefPubMed
2.
Stam K, Heisterkamp N, Reynolds FH, Groffen J: Evidence that the phl gene encodes a 160,000-dalton phosphoprotein with associated kinase activity. Mol Cell Biol. 1987, 7 (5): 1955-1960.CrossRefPubMedCentralPubMed
3.
Bhamidipati PK, Kantarjian H, Cortes J, Cornelison AM, Jabbour E: Management of imatinib-resistant patients with chronic myeloid leukemia. Ther Adv Hematol. 2013, 4 (2): 103-117. 10.1177/2040620712468289.CrossRefPubMedCentralPubMed
4.
Okabe S, Tauchi T, Katagiri S, Tanaka Y, Ohyashiki K: Combination of the ABL kinase inhibitor imatinib with the Janus kinase 2 inhibitor TG101348 for targeting residual BCR-ABL-positive cells. J Hematol Oncol. 2014, 7 (1): 37-10.1186/1756-8722-7-37.CrossRefPubMedCentralPubMed
5.
Ross DM, Branford S, Seymour JF, Schwarer AP, Arthur C, Yeung DT, Dang P, Goyne JM, Slader C, Filshie RJ, Mills AK, Melo JV, White DL, Grigg AP, Hughes TP: Safety and efficacy of imatinib cessation for CML patients with stable undetectable minimal residual disease: results from the TWISTER study. Blood. 2013, 122 (4): 515-522. 10.1182/blood-2013-02-483750.CrossRefPubMed
6.
Akinleye A, Chen Y, Mukhi N, Song Y, Liu D: Ibrutinib and novel BTK inhibitors in clinical development. J Hematol Oncol. 2013, 6: 59-10.1186/1756-8722-6-59.CrossRefPubMedCentralPubMed
7.
Mealing S, Barcena L, Hawkins N, Clark J, Eaton V, Hirji I, Davis C: The relative efficacy of imatinib, dasatinib and nilotinib for newly diagnosed chronic myeloid leukemia: a systematic review and network meta-analysis. Exp Hematol Oncol. 2013, 2 (1): 5-10.1186/2162-3619-2-5.CrossRefPubMedCentralPubMed
8.
Zhao B, Hu M: Gallic acid reduces cell viability, proliferation, invasion and angiogenesis in human cervical cancer cells. Oncol Lett. 2013, 6 (6): 1749-1755.PubMedCentralPubMed
9.
Koppikar SJ, Choudhari AS, Suryavanshi SA, Kumari S, Chattopadhyay S, Kaul-Ghanekar R: Aqueous cinnamon extract (ACE-c) from the bark of Cinnamomum cassia causes apoptosis in human cervical cancer cell line (SiHa) through loss of mitochondrial membrane potential. BMC Cancer. 2010, 10: 210-10.1186/1471-2407-10-210.CrossRefPubMedCentralPubMed
10.
Chen Y, Zhu J, Zhang W: Antitumor effect of traditional Chinese herbal medicines against lung cancer. Anti-Cancer Drugs. 2014, 25 (9): 983-991. 10.1097/CAD.0000000000000127.CrossRefPubMed
11.
Li C, Sun BQ, Gai XD: Compounds from Chinese herbal medicines as reversal agents for P-glycoprotein-mediated multidrug resistance in tumours. Clin Transl Oncol. 2014, 16 (7): 593-598. 10.1007/s12094-014-1169-7.CrossRefPubMed
12.
Zhou CX, Wu DY, Li XP, Wu YH, Zhao J, Dong N, Yu RM, Wei W, Zheng QX, Sun HD, Hao XJ, Zhao Y: [Research progress in Laggera medicinal plants]. Zhongguo Zhong Yao Za Zhi. 2006, 31 (14): 1133-1140.PubMed
13.
Ravishankar D, Rajora AK, Greco F, Osborn HM: Flavonoids as prospective compounds for anti-cancer therapy. Int J Biochem Cell Biol. 2013, 45 (12): 2821-2831. 10.1016/j.biocel.2013.10.004.CrossRefPubMed
14.
Hwang KA, Park MA, Kang NH, Yi BR, Hyun SH, Jeung EB, Choi KC: Anticancer effect of genistein on BG-1 ovarian cancer growth induced by 17 beta-estradiol or bisphenol A via the suppression of the crosstalk between estrogen receptor alpha and insulin-like growth factor-1 receptor signaling pathways. Toxicol Appl Pharmacol. 2013, 272 (3): 637-646. 10.1016/j.taap.2013.07.027.CrossRefPubMed
15.
Han YQ, Cao LJ, Hao HJ, Shi YJ: [Effects of quercetin on multidrug resistance and expression of related genes in human erythroleukemic K562/a cells]. Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2011, 19 (4): 884-889.PubMed
16.
Schumacher M, Hautzinger A, Rossmann A, Holzhauser S, Popovic D, Hertrampf A, Kuntz S, Boll M, Wenzel U: Chrysin blocks topotecan-induced apoptosis in Caco-2 cells in spite of inhibition of ABC-transporters. Biochem Pharmacol. 2010, 80 (4): 471-479. 10.1016/j.bcp.2010.04.038.CrossRefPubMed
17.
Cao CH, SW LY, Wand H, Gao MY: 3, 5-Hydroxy-6, 7, 3′, 4′-tetramethoxyflavone Isolated From Laggera pterodonta Induces CNE Cell Apoptosis. Prog Biochem Biophysics. 2011, 38 (3): 254-261.
18.
Olshen A, Tang M, Cortes J, Gonen M, Hughes T, Branford S, Quintas-Cardama A, Michor F: Dynamics of chronic myeloid leukemia response to dasatinib, nilotinib, and high-dose imatinib.Haematologica 2014. [Epub ahead of print].,
19.
Lin H, Chen M, Rothe K, Lorenzi MV, Woolfson A, Jiang X: Selective JAK2/ABL dual inhibition therapy effectively eliminates TKI-insensitive CML stem/progenitor cells. Oncotarget. 2014, 5 (18): 8637-8650.CrossRefPubMedCentralPubMed
20.
Kampa-Schittenhelm KM, Heinrich MC, Akmut F, Dohner H, Dohner K, Schittenhelm MM: Quizartinib (AC220) is a potent second generation class III tyrosine kinase inhibitor that displays a distinct inhibition profile against mutant-FLT3, −PDGFRA and -KIT isoforms. Mol Cancer. 2013, 12: 19-10.1186/1476-4598-12-19.CrossRefPubMedCentralPubMed
21.
Zhou GB, Kang H, Wang L, Gao L, Liu P, Xie J, Zhang FX, Weng XQ, Shen ZX, Chen J, Gu LJ, Yan M, Zhang DE, Chen SJ, Wang ZY, Chen Z: Oridonin, a diterpenoid extracted from medicinal herbs, targets AML1-ETO fusion protein and shows potent antitumor activity with low adverse effects on t(8;21) leukemia in vitro and in vivo. Blood. 2007, 109 (8): 3441-3450. 10.1182/blood-2006-06-032250.CrossRefPubMedCentralPubMed
22.
Zhen T, Wu CF, Liu P, Wu HY, Zhou GB, Lu Y, Liu JX, Liang Y, Li KK, Wang YY, Xie YY, He MM, Cao HM, Zhang WN, Chen LM, Petrie K, Chen SJ, Chen Z: Targeting of AML1-ETO in t(8;21) leukemia by oridonin generates a tumor suppressor-like protein. Sci Transl Med. 2012, 4 (127): 127ra138-10.1126/scitranslmed.3003562.
23.
Wajant H: The Fas signaling pathway: more than a paradigm. Science. 2002, 296 (5573): 1635-1636. 10.1126/science.1071553.CrossRefPubMed
24.
Wang J, Duan Y, Zhi D, Li G, Wang L, Zhang H, Gu L, Ruan H, Zhang K, Liu Q, Li S, Ho CT, Zhao H: Pro-apoptotic effects of the novel tangeretin derivate 5-acetyl-6,7,8,4′-tetramethylnortangeretin on mcf-7 breast cancer cells. Cell Biochem Biophys. 2014, 70 (2): 1255-1263. 10.1007/s12013-014-0049-7.CrossRefPubMed
25.
Dong Y, Cao A, Shi J, Yin P, Wang L, Ji G, Xie J, Wu D: Tangeretin, a citrus polymethoxyflavonoid, induces apoptosis of human gastric cancer AGS cells through extrinsic and intrinsic signaling pathways. Oncol Rep. 2014, 31 (4): 1788-1794.PubMed
26.
Meng FM, Yang JB, Yang CH, Jiang Y, Zhou YF, Yu B, Yang H: Vitexicarpin induces apoptosis in human prostate carcinoma PC-3 cells through G2/M phase arrest. Asian Pac J Cancer Prev. 2012, 13 (12): 6369-6374. 10.7314/APJCP.2012.13.12.6369.CrossRefPubMed
27.
Zou H, Li Y, Liu X, Wang X: An APAF-1.cytochrome c multimeric complex is a functional apoptosome that activates procaspase-9. J Biol Chem. 1999, 274 (17): 11549-11556. 10.1074/jbc.274.17.11549.CrossRefPubMed
28.
Liu B, Zhang T, Zhang X, Ye W, Li Y: Chemical constituents of Laggera pterodonta. Zhongguo Zhong Yao Za Zhi. 2010, 35 (5): 602-606.PubMed
29.
Shen Q, Liu S, Chen Y, Yang L, Chen S, Wu X, Li B, Lu Y, Zhu K, Li Y: Proliferation inhibition and apoptosis induction of imatinib-resistant chronic myeloid leukemia cells via PPP2R5C down-regulation. J Hematol Oncol. 2013, 6: 64-10.1186/1756-8722-6-64.CrossRefPubMedCentralPubMed
Metadata
Title
A polymethoxyflavone from Laggera pterodonta induces apoptosis in imatinib-resistant K562R cells via activation of the intrinsic apoptosis pathway
Authors
Changshu Cao
Bailian Liu
Chengwu Zeng
Yuhong Lu
Shaohua Chen
Lijian Yang
Bo Li
Yaolan Li
Yangqiu Li
Publication date
01-12-2014
Publisher
BioMed Central
Published in
Cancer Cell International / Issue 1/2014
Electronic ISSN: 1475-2867
DOI
https://doi.org/10.1186/s12935-014-0137-1

Other articles of this Issue 1/2014

Cancer Cell International 1/2014 Go to the issue

Primary research

Enhanced breast cancer therapy with nsPEFs and low concentrations of gemcitabine

Primary research

The immunoglobulin heavy chain VH6-1 promoter regulates Ig transcription in non-B cells

Primary research

Osteoblast inhibition by chemokine cytokine ligand3 in myeloma-induced bone disease

Primary research

miR-22 is down-regulated in esophageal squamous cell carcinoma and inhibits cell migration and invasion

Primary research

Anti-cancer activity of glucosamine through inhibition of N-linked glycosylation

Primary research

Decreased expression of the Nkx2.8 gene correlates with tumor progression and a poor prognosis in HCC cancer
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits